|
Asthma drug omalizumab cuts treatment needs
Nursing Times Severe persistent allergic asthma sufferers treated with omalizumab have been shown to use far fewer NHS resources than those treated with other drugs. The drug, marketed as Xolair, has also been shown to significantly improve users' health-related … Novartis study shows cost-effectiveness benefits of Xolair |
View full post on asthma – Google News